-
Clinical Trial
In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo.
- Ahmad Masri and Van SpallHarriette G CHGCMcMaster University, Hamilton, Ontario, Canada (H.G.V.)..
- Oregon Health & Science University, Portland, Oregon, USA (A.M.).
- Ann. Intern. Med. 2024 Mar 1; 177 (3): JC30JC30.
AbstractMaurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916.
Notes